


11<sup>th</sup> International Meeting on Cholinesterases



4-9 June 2012  
Kazan, Russia

# 11<sup>th</sup> International Meeting on Cholinesterases

---

## PROGRAM

June 4-9, 2012  
Kazan, Russia

# ORGANIZERS



Russian Academy of Sciences



Kazan (Volga Region) Federal University



Lomonosov Moscow State University



Emanuel Institute of Biochemical Physics



Kazan Scientific Center of Russian  
Academy of Sciences



Arbuzov Institute of Organic and Physical  
Chemistry



Kazan State Medical University



Kazan Institute of Biochemistry and  
Biophysics



Institute of Physiologically Active  
Compounds

Monday, 4 June 2012		
9:00		Registration Poster mounting Testing MS Power Point Presentation
16:00		<b>Opening</b> Welcome addresses
16:30-17:00		<b>Alexander Konovalov</b> (Kazan, Russia) Kazan school of chemistry: from foundation to present
17:00-17:45		<b>Sergei Varfolomeev</b> (Moscow, Russia) History of cholinesterase research in USSR and Russia
17:45-18:00		<b>Zrinka Kovarik</b> (Zagreb, Croatia) Tribute to Elsa Reiner
<b>Plenary lectures</b>		
<b>Chairpersons:</b> Patrick Masson (France), Sergei Varfolomeev (Russia)		
18:00-18.45	PL-1	<b>The EMBO Plenary lecture</b> <b>Joel Sussman</b> (Rehovot, Israel) Acetylcholinesterase: from 3D structure to drug design
18:45-19:30	PL-2	<b>Oksana Lockridge</b> (Omaha, USA) Human butyrylcholinesterase: from basic structure to medical applications
20:00		Welcome party

<b>Tuesday, 5 June 2012</b>		
<b>Session 1:</b> Structure and dynamics of cholinesterases and related $\alpha/\beta$ hydrolase-fold proteins		
<b>Chairpersons:</b> Fredrik Ekström (Sweden), Joel Sussman (Israel)		
8:00-8:20	L1-1	<b>Palmer Taylor</b> (La Jolla, USA) Approaching forty: the cholinesterases leading the $\alpha,\beta$ -hydrolase-fold structure-function quest
8:25-8:45	L1-2	<b>Pascale Marchot</b> (Marseille, France) Recent structural and mutagenesis insights into allosteric inhibition of AChE by peptidic ligands
8:50-9:00	L1-3	<b>Schroeder Noble</b> (Silver Spring, USA) Crystal structures of acetylcholinesterase in complex with novel bis-imidazoloxime reactivators
9:05-9:25	L1-4	<b>Fredrik Ekström</b> (Umeå, Sweden) Targeting acetylcholinesterase; from high throughput screening of a chemical library to quantitative structure-activity relationships
9:30-9:45	Coffee Break	
9:45-9:55	L1-5	<b>Anna Linusson</b> (Umeå, Sweden) Enantiomers define non-covalent interactions in the catalytic site of acetylcholinesterase
10:00-10:20	L1-6	<b>Judith Peters</b> (Grenoble, France) Acetylcholinesterase dynamics investigated by incoherent neutron scattering
10:25-10:45	L1-7	<b>Martin Weik</b> (Grenoble, France) Structural dynamics of acetylcholinesterase as studied by kinetic crystallography
10:50-11:00	L1-8	<b>Arlan Gonçalves</b> (Guarapari, Brazil) Molecular dynamics simulations and QM/MM studies of the reactivation by 2-PAM of tabun inhibited human acetylcholinesterase
11:05-11:15	L1-9	<b>Sofya Lushchekina</b> (Moscow, Russia) Computational modeling of hysteresis in Ala328Cys mutant of human butyrylcholinesterase
11:20-11:30	L1-10	<b>Swapna David</b> (Coimbatore, India) Why human butyrylcholinesterase L307P variant is not structurally stable: a molecular dynamics simulation study
11:35-11:50	Coffee Break	

**Session 2:** Interaction of cholinesterases with substrates, inhibitors and reactivators.

**Chairpersons:** Terrone Rosenberry (USA), Yaacov Ashani (Israel)

11:50-12:00		<b>Patrick Masson</b> (Grenoble, France) Tribute to Sergei Moralev
12:00-12:20	L2-1	<b>Israel Silman</b> (Rehovot, Israel) Reversible and irreversible inhibition of acetylcholinesterase by the photosensitizer methylene blue
12:25-12:45	L2-2	<b>Terrone Rosenberry</b> (Jacksonville, USA) The rate-limiting step for the second-order hydrolysis of acetylcholine analogs by acetylcholinesterase ( $k_{\text{cat}}/K_M$ ) is gated entry to the catalytic triad
12:50-13:10	L2-3	<b>Jure Stojan</b> (Ljubljana, Slovenia) The significance of low substrate concentration measurements for mechanistic interpretation in cholinesterases
13:15-14:15	Lunch	
14:15-14:25	L2-4	<b>Alexander Nemukhin</b> (Moscow, Russia) QM/MM approaches to resolve the catalytic mechanism of cholinesterases
14:30-14:50	L2-5	<b>Chang-Guo Zhan</b> (Lexington, USA) Reaction pathways of cholinesterases with various types of compounds: computational insights and implication for rational drug design
14:55-15:15	L2-6	<b>Paul Carlier</b> (Blacksburg, USA) Designing inhibitors for potency against the G119S resistant mutant of <i>Anopheles gambiae</i> acetylcholinesterase
15:20-15:30	L2-7	<b>Kamil Kuča</b> (Hradec Kralove, Czech Republic) Quaternary compounds designed for cholinesterase inhibition and modulation of cholinergic receptors
15:35-15:45	L2-8	<b>Donald Maxwell</b> (Aberdeen Proving Ground, USA) A common mechanism for resistance of agent-inhibited acetylcholinesterase to oxime reactivation based on QSAR of nerve agent analogues of sarin, cyclosarin and tabun
15:50-16:10	Coffee Break	

16:10-16:30	L2-9	<b>Zrinka Kovarik</b> (Zagreb, Croatia) Reactivation of tabun-phosphorylated cholinesterases probed by mutagenesis and new oximes
16:35-16:55	L2-10	<b>Apurba Bhattacharjee</b> (Silver Spring, USA) Discovery of non-oxime reactivators of OP-inhibited acetylcholinesterase (AChE) using <i>in silico</i> generated pharmacophore models
17:00-17:10	L2-11	<b>Julien Renou</b> (Rouen, France) Synthesis of new uncharged reactivators for acetylcholinesterase
17:15-17:25	L2-12	<b>Pierre-Yves Renard</b> (Rouen, France) <i>In vitro</i> evaluation of 3-hydroxy 2-pyridinaldoxime conjugates as efficient uncharged reactivators for the dephosphylation of poisoned human acetylcholinesterase

---

17:30-17:50 Coffee Break

**Session 7A:** Novel approaches to the treatment of Alzheimer disease.

**Chairpersons:** Ezio Giacobini (Switzerland), Giancarlo Pepeu (Italy)

17:50-18:10	L7A-1	<b>Ezio Giacobini</b> (Geneva, Switzerland) Cholinesterase inhibitors: from neurotoxic agents to drugs of choice to treat Alzheimer disease
18:15-18:35	L7A-2	<b>Giancarlo Pepeu</b> (Florence, Italy) Cholinesterase inhibitors affect attention and memory
18:40-19:00	L7A-3	<b>Gabriel Gold</b> (Geneva, Switzerland) Cholinesterase inhibitors in the treatment of non-Alzheimer types of dementia
19:05-19:25	L7A-4	<b>Taher Darreh-Shori</b> (Stockholm, Sweden) The role of cholinesterases in AD pathology: implications for improving efficacy of cholinesterase inhibitors
19:30-19:50	L7A-5	<b>Sultan Darvesh</b> (Halifax, Canada) Butyrylcholinesterase radioligands to image Alzheimer disease brain
19:55-20:05	L7A-6	<b>Ricardo Souza</b> (Curitiba, Brazil) Association analysis between K and -116 variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population

---

### Wednesday, 6 June 2012

**Session 3:** Anticholinesterases: Mechanisms of toxicity, detection and analytical methods, diagnosis of exposure, detoxification and therapy; counter-terrorism strategies.

**Chairpersons:** Oksana Lockridge (USA), Franz Worek (Germany)

8:00-8:20	L3-1	<b>Oksana Lockridge</b> (Omaha, USA) Mass spectrometry for detection of exposure to organophosphorus compounds
8:25-8:35	L3-2	<b>Judit Marsillach</b> (Seattle, USA) Human butyrylcholinesterase, a mass spectrometric biomarker for organophosphorus exposure
8:40-8:50	L3-3	<b>Mariya Liyasova</b> (Omaha, USA) Butyrylcholinesterase is a biomarker of exposure to tri-ortho-cresyl phosphate, an agent implicated in “aerotoxic syndrome”
8:55-9:05	L3-4	<b>Marcel van der Schans</b> (Rijswijk, The Netherlands) Methods for unequivocal assessment of exposure to chemical warfare agents based on covalent protein adducts
9:10-9:20	L3-5	<b>Robert VanDine</b> (Sarasota, USA) A point of care 10 minute assay for detection of blood protein adducts resulting from low level exposure to organophosphate nerve agents
9:25-9:45	L3-7	<b>Hermona Soreq</b> (Jerusalem, Israel) Prophylactic antagomiRs-mediated enhancement of host acetylcholinesterase protects from organophosphate poisoning
9:50-10:10	L3-8	<b>Bhupendra Doctor</b> (Silver Spring, USA) A unique combination of (-)-Huperzine A and (+)-Huperzine A effectively and reversibly inhibits acetylcholinesterase as well as reduces NMDA-induced seizures and glutamate-induced toxicity
10:15-10:35	L3-9	<b>Franz Worek</b> (Munich, Germany) Structural requirements for effective oximes — a kinetic <i>in vitro</i> study with phosphorylated human AChE and structurally different oximes
10:40-11:10	Coffee Break	

11:10-11:20	L3-10	<b>Tsung-Ming Shih</b> (Aberdeen Proving Ground, USA) Searching for an effective <i>in vivo</i> reactivator for OP nerve agent-inhibited AChE in the central nervous system
11:25-11:35	L3-11	<b>Christophor Dishovsky</b> (Sofia, Bulgaria) <i>In vitro</i> investigation of efficacy of new reactivators of cholinesterase on OPC-inhibited rat brain AChE
11:40-11:50	L3-12	<b>Janice Chambers</b> (Starkville, USA) Development of novel brain-penetrating oxime reactivators of acetylcholinesterase inhibited by organophosphates
11:55-12:05	L3-13	<b>John Graham</b> (Aberdeen Proving Ground, USA) Facilitated transport of reactivators across the blood brain barrier
12:10-12:30	L3-14	<b>Marloes Joosen</b> (Rijswijk, The Netherlands) Timing of decontamination and treatment in case of percutaneous poisoning with VX
12:35-12:55	L3-15	<b>Guy Testylier</b> (La Tronche, France) Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus. Review of the current data and perspectives

---

13:00-14:00 Lunch

---

**Session 4:** Stoichiometric and catalytic bioscavengers against anticholinesterase agents; nanobiotechnology for cholinesterases and related therapeutic aspects.

**Chairpersons:** Douglas Cerasoli (USA), Patrick Masson (France).

---

14:00-14:20	L4-1	<b>Douglas Cerasoli</b> (Aberdeen Proving Ground, USA) The protective efficacy of human butyrylcholinesterase against exposure to organophosphorus nerve agents
14:25-14:45	L4-2	<b>Helen Mumford</b> (Salisbury, UK) Human plasma-derived BuChE as a stoichiometric bioscavenger for treatment of nerve agent poisoning
14:50-15:00	L4-3	<b>Yvonne Rosenberg</b> (Rockville, USA) Protection by aerosolized recombinant macaque butyrylcholinesterase against aerosolized paraoxon exposure in homologous macaques



15:05-15:25	L4-4	<b>Tsafrir Mor</b> (Tempe, USA) Plant-produced butyrylcholinesterase variants as versatile bioscavengers
15:30-15:50	L4-5	<b>Nageswarao Chilukuri</b> (Aberdeen Proving Ground, USA) The use of adenovirus to deliver therapeutic levels of bioscavengers against anticholinesterase agents
15:55-16:25	Coffee Break	
16:25-16:45	L4-6	<b>Yakov Ashani</b> (Rehovot, Israel) Analysis of the inputs required for estimating catalytic scavenger doses needed to protect against OP intoxication
17:50-17:10	L4-7	<b>Moshe Goldsmith</b> (Rehovot, Israel) Directed evolution of serum paraoxonase 1 for broad spectrum G-agent hydrolysis
17:15-17:25	L4-8	<b>Tamara Otto</b> (Aberdeen Proving Ground, USA) Identification and characterization of novel catalytic bioscavengers
17:30-17:40	L4-9	<b>Manojkumar Valiyaveetil</b> (Silver Spring, USA) Crossroads in therapeutic evaluation of paraoxonase 1 in nerve agent toxicity
18.45-18.05		<b>Elena Efremenko</b> (Moscow, Russia) Bacterial phosphotriesterases, effective enzymes for degradation of OPs: genetic engineering, applications to destruction of CWA and decontamination
19:00	Conference dinner	

---

**Thursday, 7 June 2012**


---

**Session 4:** Stoichiometric and catalytic bioscavengers against anticholinesterase agents; nanobiotechnology for cholinesterases and related therapeutic aspects (continued)

**Chairpersons:** Douglas Cerasoli (USA), Patrick Masson (France).

---

8:00-8:10	L4-10	<b>Sean Hodgins</b> (Aberdeen Proving Ground, USA) Biochemical characterization and <i>in vivo</i> anti-OP protective efficacy of recombinant huPON1 expressed in <i>Trichoplusia ni</i> larvae
8:15-8:25	L4-11	<b>Shane Kasten</b> (Aberdeen Proving Ground, USA) The <i>in vitro</i> specificity and <i>in vivo</i> protective efficacy of PON1 variants against exposure to organophosphorus nerve agents
8:30-8:50	L4-12	<b>Alexander Kabanov</b> (Moscow, Russia) Nanozymes as potential bioscavengers for prevention and reparation of damage caused by OP compounds
8:55-9:05	L4-13	<b>Stephen Kirby</b> (Aberdeen Proving Ground, USA) An engineered mutant of human platelet activating factor acetylhydrolase hydrolyzes organophosphorus nerve agents
9:10-9:20	L4-14	<b>Robert diTargiani</b> (Aberdeen Proving Ground, USA) Catalytic activity of human prolidase and its variants against nerve agents
9:25-9:55	Coffee Break	
9:55-10:05	L4-15	<b>Pierre-Yves Renard</b> (Rouen, France) Strategies for the selection of catalytic antibodies against OP nerve agents
10:10-10:30	L4-16	<b>Alexander Gabibov</b> (Moscow, Russia) Catalytic antibodies reacting with OP compounds
10:35-10:45	L4-17	<b>François Estour</b> (Rouen, France) Functionalized cyclodextrins – a promising way to degrade nerve agents
10:50-11:10	L4-18	<b>Steve Brimijoin</b> (Rochester, USA) Progress toward gene transfer of modified human BuChE as a therapy for cocaine addiction

11:15-11:25	L4-19	<b>Yang Gao</b> (Rochester, USA) Cocaine hydrolase and anti-cocaine antibody combine to reduce cocaine stimulation and toxicity
11:30-12:00	Coffee Break	
<b>Session 5:</b> Enzymes other than cholinesterases reacting with anticholinesterase agents.		
<b>Chairpersons:</b> Clement Furlong (USA), Galina Makhaeva (Russia)		
12:00-12:20	L5-1	<b>John Casida</b> (Berkeley, USA) Anticholinesterase insecticide retrospective
12:25-12:45	L5-2	<b>Philip Potter</b> (Memphis, USA) Carboxylesterases as targets for anticholinesterase agents
12:50-13:10	L5-3	<b>Rudy Richardson</b> (Ann Arbor, USA) Neuropathy target esterase: overview and future
13:15-13:35	L5-4	<b>Clement Furlong</b> (Seattle, USA) Tert-butylated triaryl phosphates are not readily metabolized to serine esterase inhibitors
13:40-14:40	Lunch	
14:40-15:00	L5-5	<b>Eugenio Vilanova</b> (Elche, Spain) Differential interactions of neuropathy inducers, non-inducers and promoters with soluble and membrane esterases: Kinetic approaches
15:05-15:25	L5-6	<b>Galina Makhaeva</b> (Chernogolovka, Russia) Organophosphorus compound esterase profiles as predictors of therapeutic and toxic effects
15:30-15:50	L5-7	<b>Dragomir Draganov</b> (Ashland, USA) How does Paraoxonase 1 work <i>in vivo</i> – the indirect model
15:55-16:15	L5-8	<b>Giuseppe Manco</b> (Napoli, Italy) Hyperthermophilic phosphotriesterases/lacton- ases: structure, function and possible applications
16:20-16:50	Coffee Break	

---

**3D Session**

**Chairpersons:** Zoran Radić (USA), Martin Weik (France)

---

- |             |      |  |
|-------------|------|--|
| 16:50-17:20 | 3D-1 | <b>Florian Nachon</b> (La Tronche, France)<br>Structural aspects of the inhibition of cholinesterases by cresyl saligenin phosphate (CBDP)       |
| 17:25-17:55 | 3D-2 | <b>Zoran Radić</b> (La Jolla, USA)<br>Mechanism of interaction of novel uncharged, centrally active reactivators with OP-hAChE conjugates        |
| 18:00-18:15 | 3D-3 | <b>Rathanam Boopathy</b> (Coimbatore, India)<br>Structure based repurposing of FDA approved drugs as acetylcholinesterase inhibitors             |
| 18:20-18:50 | 3D-4 | <b>Eric Chabrière</b> (Marseille, France)<br>Structural Biology contributions in the understanding and increase of phosphotriesterase activities |
-

**Friday, 8 June 2012**

**Session 6:** Molecular biology and cell biology of cholinesterases and alternative functions of cholinesterases.

**Chairpersons:** Karl Tsim (China), Arnaud Chatonnet (France)

9:00-9:10		<b>Claire Legay</b> (Paris, France) Tribute to Jean Massoulié
9:10-9:30	L6-1	<b>Claire Legay</b> (Paris, France) Developmental consequences of the ColQ/MuSK interaction
9:35-9:55	L6-2	<b>Karl Tsim</b> (Hong Kong, China) Molecular assembly of PRiMA-linked acetylcholinesterase: the roles of t-peptide, FHB domain and N-linked glycosylation
10:00-10:10	L6-3	<b>Paul Layer</b> (Darmstadt, Germany) Alternative functions of cholinesterases during embryonic development of chick and mouse
10:15-10:25	L6-4	<b>Janez Sketelj</b> (Ljubljana, Slovenia) Several mechanisms regulate acetylcholinesterase-associated collagen Q expression in slow and fast muscle fibers of rat muscles
10:30-11:00	Coffee Break	
11:00-11:20	L6-5	<b>Leo Pezzementi</b> (Birmingham, USA) Do the MRL proteins - MIG-10, RIAM, and lamellipodin - interact with acetylcholinesterase and butyrylcholinesterase?
11:25-11:45	L6-6	<b>Susan Greenfield</b> (Oxford, UK) Non-hydrolytic effects of AChE: the actions of peptides derived from the C-terminal
11:50-12:10	L6-7	<b>Zoran Grubič</b> (Ljubljana, Slovenia) Classical and alternative roles of acetylcholinesterase in the <i>in vitro</i> innervated human skeletal muscle
12:15-12:25	L6-8	<b>Astrid Vogel-Höpker</b> (Darmstadt, Germany) Alternative cholinolytic function of Acetylcholinesterase in skeletogenesis

12:30-12:40	L6-9	<b>Nicolas Lenfant</b> (Montpellier, France) Proteins with an $\alpha/\beta$ hydrolase fold: how to decipher new functions in an ever growing superfamily?
<hr/>		
12:45-13:45	Lunch	
<hr/>		
13:45-13:55	L6-10	<b>Xue Jun Zhang</b> (Shanghai, China) Regulation of acetylcholinesterase expression in cell apoptosis
14:00-14:10	L6-11	<b>Anthony Turner</b> (Leeds, UK) Acetylcholinesterase and Alzheimer's disease: novel interactions and regulatory mechanisms
14:15-14:25	L6-12	<b>Yifan Han</b> (Hong Kong, China) Novel dimeric anticholinesterases derived from Chinese herb: molecular basis for unexpected neuroprotection via multiple targets
14:30-14:40	L6-14	<b>Ebru Bodur</b> (Ankara, Turkey) Effects of exercise and conjugated linoleic acid (CLA) usage on BChE and obesity in men
<hr/>		
16:00	Excursion	
<hr/>		

**Saturday, 9 June 2012**

**Session 7B:** Diseases related to cholinesterases, and cholinesterase inhibitors therapy.

**Chairpersons:** Eric Krejci (France), Enver Bogdanov (Russia)

9:00-9:20	L7B-1	<b>Kinji Ohno</b> (Nagoya, Japan) Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis
9:25-9:35	L7B-2	<b>Lupe Furtado-Alle</b> (Curitiba, Brazil) -116A and K BCHE gene variants associated with obesity and hypertrygliceridemia in adolescents from Southern Brazil
9:40-9:50	L7B-3	<b>Ricardo Souza</b> (Curitiba, Brazil) Copy number variation at 7q22 and 3q26 in sporadic breast cancer
9:55-10:15	L7B-4	<b>Eric Krejci</b> (Paris, France) A novel insight into acetylcholinesterase functions in the nervous system provided by the mutant mice
10:20-10:40	L7B-5	<b>Cecilio Vidal</b> (Murcia, Spain) The AChE membrane binding tail PRiMA is down-regulated in muscle and nerve of mice with muscular dystrophy by merosin deficiency
10:45-11:15	Coffee Break	
11:15-11:25	L7B-6	<b>Anna Hrabovska</b> (Bratislava, Slovakia) Studying cholinesterases in biological samples
11:30-11:40	L7B-7	<b>Ian Macdonald</b> (Halifax, Canada) Radioligands for imaging cholinesterases in brain
11:45-12:05	L7B-8	<b>Konstantin Petrov</b> (Kazan, Russia) Tissue-specific inhibitors of acetylcholinesterase for treatment of myasthenia gravis
12:25-12:35	L7B-9	<b>Irina Kovyazina</b> (Kazan, Russia) Nitric oxide is an endogeneous regulator of acetylcholinesterase activity in mammalian neuromuscular junction

12:40-12:50	L7B-10	<b>Madhusoodana P. Nambiar</b> (Silver Spring, USA) Modulation of cholinergic pathways in blast-induced traumatic brain injury
12:55-13:10	L7B-11	<b>Natalya Zalutskaya</b> (St.Petersburg, Russia) Results of monotherapy in patients with Alzheimer's disease and vascular dementia by anticholinesterase drug Axamon

---

13:15-14:15 Lunch

---

**3D Session (continued)**

**Chairpersons:** Zoran Radić (USA), Martin Weik (France)

---

14:15-14:45	3D-5	<b>Yves Bourne</b> (Marseille, France) Structural bases for a novel mechanism of AChE inhibition
14:50-15:20	3D-6	<b>Yechun Xu</b> (Shanghai, China) The dynamic behavior of residues along the long active-site gorge of AChE and their relationship to the ligand traffic
15:25-15:40	3D-7	<b>Gianluca Santoni</b> (Grenoble, France) Conformational variabilities in human and <i>Torpedo californica</i> acetylcholinesterases studied by MD simulations and kinetic crystallography
15:45-16:15	3D-8	<b>Jacques-Philippe Colletier</b> (Grenoble, France) Structural evidence for the interaction of acetylcholinesterase and the amyloid-beta peptide

---

16:20-16:50 Coffee Break

---

17:00

**Closing**

**Patrick Masson** (Grenoble, France), **Zoran Radić** (La Jolla, USA)

Summing up of the 11<sup>th</sup> Meeting on Cholinesterases

**Farewell addresses**

---



## LIST OF POSTERS

### Session 1: Structure and dynamics of cholinesterases and related $\alpha/\beta$ hydrolase-fold proteins.

- P1-1. PROLINE RICH PEPTIDES FROM SOLUBLE TETRAMERIC FETAL BOVINE SERUM ACETYLCHOLINESTERASE AND HORSE BUTYRYLCHOLINESTERASE  
**K. Biberoglu**, L.M. Schopfer, A. Saxena, O. Tacal, O. Lockridge
- P1-2. COMPUTATIONAL STUDY OF THE CHOLINESTERASE DYNAMICS  
**D.A. Novichkova**, S.V. Luschekina, P. Masson, A.V. Nemukhin, S.D. Varfolomeev
- P1-3. ANALYSIS AND COMPARISON OF 3D-STRUCTURES OF ACETYLCHOLINESTERASE  
V.S. Polomskih, **S.V. Luschekina**, A.V. Nemukhin, S.D. Varfolomeev
- P1-4. DYNAMICS, ACTIVITY AND STABILITY RELATIONSHIP WITHIN THE CHOLINESTERASE FAMILY  
**M.Trovaslet**, M. Trapp, F.Nachon, M.Tehei, M.Weik, P.Masson, J.Peters

### Session 2: Interaction of cholinesterases with substrates, inhibitors and reactivators.

- P2-1. THE ACETYLCHOLINESTERASE SITES EFFECTS ON THE INTERACTION OF SER203 WITH PYRIDOXINE DERIVATIVES  
**R. Ch. Ayupov**, N.I. Akberova, D.S. Tarasov
- P2-2. EXPLORING THE LIGAND-BINDING PROPERTIES OF ACETYLCHOLINESTERASE - THE IMPORTANCE OF WEAK HYDROGEN BONDS  
**L. Berg**, Fr. Ekström, A. Linusson
- P2-3. SCREENING FOR NATURALLY OCCURRING P-SITE INHIBITORS OF ACETYLCHOLINESTERASE THAT BLOCK ORGANOPHOSPHATE INACTIVATION  
V. Beri, **T. Rosenberry**
- P2-4. A COMPUTATIONAL PERSPECTIVE OF MOLECULAR INTERACTIONS THROUGH PHARMACOPHORE BASED VIRTUAL SCREENING FOR IDENTIFYING POTENTIAL BIVALENT INHIBITORS OF NATURAL ORIGIN AGAINST HUMAN ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE  
L. Venkatachalam, S. K. Venkatesan, E. Selvaraj, **R. Boopathy**

- P2-5. STRUCTURE-ACTIVITY RELATIONSHIP IN INTERACTIONS OF CHOLINESTERASES WITH BISDIMETHYLCARBAMATES  
**A. Bosak**, I. Gazić, V. Vinković, G. Šinko, A. Štimac, Z. Kovarik
- P2-6. OXIME REACTIVATION OF NERVE AGENT-INHIBITED ACETYLCHOLINESTERASE (ACHE) PROBED USING RECOMBINANT HUMAN ACHE MUTANT ENZYMES  
**C. Chambers**, C. Luo, A. Saxena
- P2-7. STRUCTURES OF RECOMBINANT HUMAN ACETYLCHOLINESTERASE COMPLEXED WITH FAS-2 WITH BOUND ACTIVE SITE INHIBITORS  
**J. Cheung**, M. Franklin, M. Rudolph, F. Burshteyn, M. Cassidy, E. Gary, J. Height, W. Hendrickson, W. Appel
- P2-8. EFFECT OF DIFFERENT BUFFERS ON ELLMAN'S REAGENT ACTION  
**D. Dingová**, A. Hrabovská
- P2-9. HI-6 AND OBIDOXIME IMPLICATION IN OXIDATIVE STRESS: GUINEA PIG MODEL  
**L. Drtinova**, M. Pohanka, V. Sepsova, F. Zemek, J. Zdarova Karasova, Z. Krenkova, J. Misik, J. Korabecny
- P2-10. MOLECULAR ASPECTS OF THE REACTIVATION OF ACETYLCHOLINESTERASE INHIBITED BY THE CARBAMATE CARBOFURAN  
K.S. Matos, **T.C.C. França**, E.F.F. Cunha, T.C. Ramalho, K. Kuca
- P2-11. DOCKING STUDIES OF SARIN-INHIBITED ACETYLCHOLINESTERASE: MOLECULAR DOCKING VERSUS *IN VITRO* DATA  
**T.C.C. França**, J.S.F.D. Almeida, A.P. Guimarães, M. N. Rennó, T.C. Ramalho, A.S. Gonçalves, M.C. de Koning
- P2-12. INTERACTIONS OF PYRIDINIUM OXIMES WITH THE PERIPHERAL ALOSTERIC SITE LIMIT THEIR EFFICIENCY IN REACTIVATION OF PHOSPHORYLATED AChE  
**M. Katalinić**, N. Maček, G. Šinko, Z. Kovarik
- P2-13. IDENTIFICATION OF COMPOUNDS THAT PROTECT AND REACTIVATE ACETYLCHOLINESTERASE  
**F.S. Katz**, L. Schneider, M. Luzac, A. Hastings-Robinson, D.W. Landry, M.N. Stojanovic
- P2-14. SYNTHESIS, BIOLOGICAL ASSESSMENT AND MOLECULAR MODELING OF NOVEL TACRINE-7 METHOXYTACRINE HETERODIMERS FOR ALZHEIMER DISEASE TREATMENT  
**J. Korabecny**, S. Hamuľakova, K. Babkova, A. Horova, K. Musilek, K. Spilovska, J. Imrich, V. Opletalova, Z. Gazova, J. Zdarova Karasova, J. Hroudova, Z. Fisar, L. Gaľa, M. Valko, J. Kassa, K. Kuca

- P2-15. STUDY OF NEW DERIVATES OF CARBAMATES AND THEIR INHIBITION OF ACETYLCHOLINESTERASE  
**M. Kovářová**, K. Komers, Š. Štěpánková
- P2-16. KINETICS AND COMPUTATIONAL PREDICTIONS OF FLUORINATED CARBETHOXY 1-AMINOPHOSPHONATE REACTIVITY WITH SERINE ESTERASES  
**S.V. Lushchekina**, **G.F. Makhaeva**, O.G. Serebryakova, A.Y. Aksinenko, R.J. Richardson
- P2-17. COMPUTATIONAL MODELING OF INTERACTION BETWEEN CHOLINESTERASES AND CRESYL SALIGENIN PHOSPHATE  
**S.V. Lushchekina**, V.S. Polomskih, P. Masson, A.V. Nemukhin, S.D. Varfolomeev
- P2-18. EXPLORING THE PERIPHERAL SITE OF BUTYRYLCHOLINESTERASE  
**I.R. Macdonald**, E. Martin, S. Darvesh
- P2-19. NOVEL AND RE-EVALUATED ACTIVITIES IN THE SERIES OF N-ALKYLATED-TACRINE DERIVATIVES: SYNTHESIS, BIOLOGICAL EVALUATION AND MOLECULAR MODELING  
J. Korabecny, **E. Nepovimova**, L. Janovec, A. Horova, F. Zemek, K. Musilek, K. Spilovska, V. Opletalova, K. Kuca
- P2-20. THE RESEARCH OF BUTYRYLCHOLINESTERASE SENSITIVITY TO DIISOPROPYL FLUOROPHOSPHATE IN THE PRESENCE OF OCTANOL  
E.Yu. Bykovskaja, Yu.G. Zhukovskij, L.P. Kuznetsova, E.R. Nikitina, **E.E. Sochilina**
- P2-21. THE DETERMINATION OF RATE CONSTANTS OF ELEMENTARY STAGES OF REACTION BUTYRYLCHOLINESTERASE WITH DIISOPROPYL FLUOROPHOSPHATE  
V.A. Samokish, L.P. Kuznetsova, **E.E. Sochilina**
- P2-22. DETERMINATION OF BINDING POINTS OF METHYLENE BLUE ON HUMAN BUTYRYLCHOLINESTERASE  
**O. Tacal**, Z. Sezgin, K. Biberoglu, V. Chupakhin, G. Makhaeva
- P2-23. NEW CONCEPT FOR REACTIVATING AGED CHOLINESTERASES - STRUCTURAL STUDY  
**M. Wandhammer**, M. de Koning, D. Noort, M. Goeldner, F. Nachon
- P2-24. ANTHRAQUINONES FROM *RHEUM PALMATUM* INHIBIT ACETYLCHOLINESTERASE ACTIVITY IN VITRO  
**Y. Wang**, H. Lin, L. S. Li, D.C.C. Wan

- P2-25. KINETIC, PHARMACOLOGICAL, AND TOXICOLOGICAL CONSEQUENCES OF THE G119S RESISTANCE MUTATION IN ACETYLCHOLINESTERASE-1 OF *ANOPHELES GAMBIAE* (AKRON)  
**D.M. Wong**, J. Li, Q. Han, J.M. Mutunga, A.Wysinski, T.D. Anderson, H. Ding, T.L. Carpenetti, S.L. Paulson, P.C.-H. Lam, M.M. Totrov, J.R. Bloomquist, P.R. Carlier

**Session 3: Anticholinesterases: Mechanisms of toxicity, detection and analytical methods, diagnosis of exposure, detoxification and therapy; counter-terrorism strategies.**

- P3-1. STUDY ON ESTERASE STATUS OF PARAOXON-POISONED RATS AND TREATED WITH AN OXIME-TYPE CHOLINESTERASE REACTIVATOR  
**V. Atanasov**, I. Petrova, C. Dishovsky
- P3-2. AN INSIGHT IN TABUN TOXICITY THROUGH THE MEASUREMENT OF BIOMARKERS OF OXIDATIVE STRESS IN BLOOD AND BRAIN OF EXPOSED RATS  
**S. Berend**, N. Kopjar, A.L. Vrdoljak
- P3-3. A PHARMACOKINETIC PROFILE OF HI-6 DMS IN THE CONSCIOUS GUINEA PIG  
**A. R. Cook**, N. Roughley, S. Stubbs, I. Scott, R. Erskine, A.C. Green, J. Tattersall
- P3-4. SCREEN-PRINTED GRAPHITE ELECTRODES MODIFIED WITH MANGANESE DIOXIDE FOR ANALYSIS OF BUTYRYLCHOLINESTERASE AND ITS INHIBITORS  
**A.V. Eremenko**, E.A. Dontsova, A.P. Nazarov, E.G. Evtushenko, I.N. Kurochkin
- P3-5. A NEW SCREEN-PRINTED CHOLINE OXIDASE BIOSENSOR FOR BLOOD CHOLINESTERASES ASSAY AND DETECTION OF EXPOSURE TO ORGANOPHOSPHORUS COMPOUNDS (OPC).  
M.S. Gromova, L.V. Sigolaeva, N.A. Krainova, **A.V. Eremenko**, E.V. Rudakova, **G.F. Makhaeva**, I.N. Kurochkin
- P3-6. ELECTROCHEMICAL ENZYME BIOSENSORS BASED ON ACHE  
I.V. Rosin, S.S. Babkina, **A.G. Goryunova**
- P3-7. INDUCTION OF PLASMA ACETYLCHOLINESTERASE ACTIVITY AND APOPTOSIS IN MICE TREATED WITH TRI-O-CRESYL PHOSPHATE  
**W. Jiang**, E.G. Duysen, O. Lockridge
- P3-8. THE BENEFIT OF COMBINATIONS OF ACETYLCHOLINESTERASE REACTIVATORS FOR THE ANTIDOTAL TREATMENT OF POISONINGS WITH ORGANOPHOSPHORUS COMPOUNDS  
**J. Kassa**, J. Zdarova Karasova, K. Kuca, K. Musilek, J. Bajgar

- P3-9. THE CHOLINERGIC AND NON-CHOLINERGIC EFFECTS OF ORGANOPHOSPHATES AND OXIMES IN CULTURED HUMAN MYOBLASTS  
**M. Katalinić**, K. Miš, Z. Grubič, Z. Kovarik, T. Marš
- P3-10. HIGH RESOLUTION GC-MS FOR DETECTION OF SARIN AND SOMAN IN BIOLOGICAL SAMPLES  
**N. Koryagina**, E. Savelieva, V. Kopeikin, D. Prokofieva, N. Voitenko, N. Goncharov
- P3-11. CHOLINESTERASE BIOSENSORS IN DETERMINATION OF SOME MYCOTOXINS  
**E.P. Medyantseva**, H.M.T. Thanh, R.M. Varlamova, E.Yu. Tarasova, G.R.Sakhapova, S.S. Babkina, H.C. Budnikov
- P3-12. CHOLINESTERASE AS A LABEL IN AMPEROMETRIC ENZYME IMMUNOASSAY  
**E. Medyantseva**, G. Safina, E. Khaldeeva, H. Budnikov
- P3-13. THE DEVELOPEMENT NEW METHOD TO MEASURE ACTIVITY OF BUTYRYLCHOLINESTERASE  
**K. Mrvová**, A. Hrabovská
- P3-14. PHOSPHOPROTEOMICS APPROACH FOR DETECTION OF BUTYRYLCHOLINESTERASE ADDUCTS WITH ORGANOPHOSPHOROUS NERVE AGENTS BY MALDI MASS SPECTROMETRY  
**E.A. Murashko**, Y.A. Dubrovsky, V.I. Shmurak, A.D. Nadeev, E.P. Podolskaya, V.N. Babakov
- P3-15. PRX-105: A NOVEL BIOLOGICAL COUNTERMEASURE FOR NERVE AGENTS  
Y. Shaaltiel, H. Soreq, J. Atsmon, E. Brill-Almon, D. Bartfeld, A. Shulman, **C. Nadri-Shay**, R. Chertkoff, D. Aviezer
- P3-16. ACETYLCHOLINESTERASE SPECIFIC ACTIVITY IN BLOOD AND TISSUES FROM MULTIPLE SPECIES  
C. McElroy, K. McGarry, C. Wilhelm, R. Bartlett, **D. Read**
- P3-17. THE DEVICE FOR THE MEASUREMENT OF CHOLINESTERASE ACTIVITY IN HUMAN BLOOD  
**O. Tanyukhina**, E. Lange, S. Lobiakina, A. Radilov
- P3-18. BIOSENSORS BASED ON IMMOBILIZATION OF ACETYLCHOLINESTERASE  
**K. Vorčáková**, Š. Štěpánková

**Session 4: Stoichiometric and catalytic bioscavengers against anticholinesterase agents; nanobiotechnology for cholinesterases and related therapeutic aspects.**

- P4-1. BEHAVIORAL SAFETY AND PROTECTIVE ACTIVITY OF HUMAN BLOOD PLASMA BUTYRYLCHOLINESTERASE: AN ACOUSTIC STARTLE REFLEX STUDY  
A.V. Kholina, T.I. Novozhilova, I.I. Kashnikova, **K.A. Anikienko**
- P4-2. TREATMENTS FOR PERCUTANEOUS VX POISONING  
**S.J. Armstrong**, C.J. Docx
- P4-3. BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF A SELF-REACTIVABLE BUTYRYLCHOLINESTERASE.  
**X. Brazzolotto**, F. Worek, F. Dorandeu, F. Nachon
- P4-4. PROGRESS TOWARDS BCHE TETHERED WITH A REACTIVATING LIGAND: A PSEUDO-CATALYTIC NERVE AGENT BIOSCAVENGER  
**M.C. de Koning**, F. Nachon, X. Brazzolotto, M. Trovaslet, D. Noort
- P4-5. DEVELOPMENT OF A LOW COST BIODECONTAMINANT BY RATIONAL DIRECTED EVOLUTION  
**J. Hiblot**, M. Elias, G. Gotthard, P. Masson, E. Chabriere
- P4-6. SIALYLATION AS A NOVEL APPROACH FOR LONG-LIVING RECOMBINANT HUMAN BUTYRYLCHOLINESTERASE.  
**D.G. Ilyushin**, I.V. Smirnov, P. Masson, I.A. Dyachenko, T.I. Novojilova, E.A. Bychihin, G. Gregoriadis, D.D. Genkin, K.A. Anikienko, A.N. Murashev, N.A. Ponomarenko, A.G. Gabibov.
- P4-7. EVALUATION OF REACTIVATING EFFICACY OF NEW OXIMES FOR PREPARATION OF "PSEUDOCATALYTIC SCAVENGER" BASED ON BUTYRYLCHOLINESTERASE  
**Z. Krenkova**, K. Musilek, K. Kuca, L. Drtinová, V. Šepsová, D. Jun
- P4-8. QM/MM MODELING OF THE G117H BUTYRYLCHOLINESTERASE CATALYZED ECHOTHIOPHATE HYDROLYSIS REACTION MECHANISM  
**S.V. Lushchekina**, P. Masson, F. Nachon, A.V. Nemukhin, S.D. Varfolomeev
- P4-9. NOVEL APPROACHES FOR ENHANCING IN VIVO RETENTION OF RECOMBINANT HUMAN PROLIDASE  
**R.S. Naik**, C.P. Chambers, L. Chandrasekaran, W. Sun, A. Saxena
- P4-10. AMINO ACID RESIDUES AT THE N- AND C-TERMINI ARE ESSENTIAL FOR THE FOLDING OF ACTIVE HUMAN BUTYRYLCHOLINESTERASE POLYPEPTIDE  
**R.S. Naik**, N. Pattabiraman, A. Saxena

- P4-11. CONVERTING BUTYRYLCHOLINESTERASE FROM STOICHIOMETRIC TO CATALYTIC BIOSCAVENGER  
**Z. Radić**, T. Dale, E. Garcia, L. Zhang, S. Berend, Z. Kovarik, G. Amitai, D. Ajami, J. Rebek, P. Taylor
- P4-12. PARAOXONASE-1 ACTIVITY IN ACUTE ORGANOPHOSPHATE POISONING  
 I. Kurdyukov, **N. Voitenko**, V. Shmurak, D. Prokofieva, N. Goncharov

**Session 5: Enzymes other than cholinesterases reacting with anticholinesterase agents.**

- P5-1. PMSF ALTERS THE INTERACTION OF CHICKEN BRAIN ESTERASES WITH ORGANOPHOSPHOROUS COMPOUNDS.  
 I. Mangas, **J. Estevez**, E. Vilanova
- P5-2. ENZYMATIC DECONTAMINATION OF ORGANOPHOSPHORUS NERVE AGENTS  
**H. Groombridge**, M. Salt
- P5-3. COMPREHENSIVE ANALYSIS OF SURFACE CHARGED RESIDUES INVOLVED IN THERMAL STABILITY IN *ALICYCLOBACILLUS ACIDOCALDARIUS* ESTERASE 2  
 M. Pezzullo, P. Del Vecchio, L. Mandrich, **R. Nucci**, G. Manco
- P5-4. DETERMINATION OF KINETIC CONSTANTS FOR THE INTERACTION BETWEEN SOMAN AND ALBUMIN WITH HPLC-MS IN EXPERIMENTAL CONDITIONS APPROXIMATING TO THOSE IN VIVO  
**D. Prokofieva**, V. Shmurak, G. Karakashev, N. Goncharov
- P5-5. LOW TOXIC SELECTIVE CARBOXYLESTERASE INHIBITOR FOR PRECLINICAL STUDY OF HYDROLYTICALLY UNSTABLE DRUGS  
**E.V. Rudakova**, G.F. Makhaeva, R.J. Richardson
- P5-6. MOUSE MODEL FOR BIOCHEMICAL ASSESSMENT OF NEUROPATHIC POTENTIAL OF ORGANOPHOSPHORUS COMPOUNDS (OPC)  
**N. P. Boltneva**, **E.V. Rudakova**, G.F. Makhaeva, O.G. Serebryakova, R.J. Richardson
- P5-7. MOLECULAR MODELING STUDY ON SOMAN BINDING TO ALBUMIN  
 D. Belinskaya, **V. Shmurak**, D. Prokofieva, N. Goncharov
- P5-8. MODULATION OF CARBOXYLESTERASE ACTIVITY BY CHOLINESTERASE INHIBITORS  
**L. Tsurkan**, M.J.Hatfield, J.L. Hyatt, C.C. Edwards, P.M. Potter

- P5-9. THE ABSENCE OF NEUROPATHY TARGET ESTERASE (NTE) EXPRESSION ALTERS NEURODEVELOPMENT: EVIDENCES OF A BIOLOGICAL BASIC FUNCTION OF NTE  
D. Pamies, C. Estevan, M.A. Sogorb, **E. Vilanova**

**Session 6: Molecular biology and cell biology of cholinesterases and alternative functions of cholinesterases.**

- P6-1. CHARACTERIZATION AND ITS INTERACTION OF RAT INTESTINAL BUTYRYLCHOLINESTERASE WITH STATIN COMPOUNDS  
**E. Bodur**
- P6-2. EFFECTS OF EXERCISE AND CONJUGATED LINOLEIC ACID (CLA) USAGE ON BCHE AND OBESITY IN MEN  
**S. Bulut**, E. Bodur, R. Colak, H. Turnagol, A.N. Cokugras.
- P6-3. MOLECULAR DYNAMICS AND PROTECTION STUDIES ELUCIDATE THE ARYL ACYLAMIDASE ACTIVITY OF ACETYLCHOLINESTERASE IS MEDIATED THROUGH THE SIDE DOOR OF THE ENZYME  
**R. Chinnaduraia**, C. Loganathana, R. Boopathya
- P6-4. ROLE OF MUSK-COLQ INTERACTIONS IN SYNAPTOGENESIS OF THE NEUROMUSCULAR JUNCTION  
**A. Dobbertin**, S. Sigoillot, F. Bourgeois, J. Karmouch, C. Legay
- P6-5. CHARACTERIZATION OF ACETYLCHOLINESTERASE IN *CRASSOSTREA GIGAS*, A LOCAL OYSTER IN CHINA  
**T.T.X. Dong**, G.C. Zha, V.P. Chen, W.K.B. Chan, W.K.W. Luk, R.C.Y. Choi, K.W.K. Tsim
- P6-6. PLANT EXPRESSION AND CHARACTERIZATION OF COCAINE HYDROLYZING MUTANTS OF BUTYRYLCHOLINESTERASE  
**K. Larrimore**, L. Kannan, M. Barcus, B. Geyer, S. Brimijoin, J. Neisewander, T. Mor
- P6-7. ESTHER UPDATE: A GROWING UP DATABASE ON EVOLUTIONARY DIVERSE MEMBERS OF THE ALPHA/BETA HYDROLASE FOLD SUPERFAMILY  
**N. Lenfant**, T. Hotelier, Y. Bourne, P. Marchot, A. Chatonnet
- P6-8. THE MOLECULAR ASSEMBLY OF DIMERIC FORM OF ACETYLCHOLINESTERASE IN ERYTHROCYTE: THE ROLE OF GLYCOSYLATION AND CARBOXYLIC TERMINUS  
**W.K.W. Luk**, V.P. Chen, R.C.Y. Choi, W.K.B. Chan, K.W.K. Tsim



- P6-9. EFFECT OF HYPOXIA ON CHOLINESTERASES IN RAT BRAIN CORTEX AND HUMAN NEUROBLASTOMA CELLS IN CULTURE  
**N.N. Nalivaeva**, E.G. Kochkina, N.Z. Makova, S.A. Plesneva, A.J. Turner, I.A. Zhuravin
- P6-10. IMMUNOEXPRESSION OF ACETYLCHOLINESTERASE IN NEUROMUSCULAR JUNCTION OF FAST AND SLOW MUSCLES OF RATS UNDER MODELING OF HYPOGRAVITATION  
**L.F. Nurullin**, O.V. Tyapkina
- P6-11. CHOLINESTERASES IN *SACCOGLOSSUS KOWALEVSKII* (HEMICHORDATA): CLONING, *IN VITRO* EXPRESSION, AND MOLECULAR CHARACTERISATION.  
**L. Pezzementi**, N. Lenfant, A. Chatonnet
- P6-12. PC12 CELLS AS A RELIABLE MODEL FOR CHARACTERIZING BIOACTIVITY OF ACHE PEPTIDES.  
**S.G. Ratés**, R.E. Worrall, S. Greenfield
- P6-13. ROLES OF ACETYLCHOLINESTERASE DURING NEURONAL DIFFERENTIATION OF EMBRYONIC STEM CELLS  
**L.E. Sperling**, M. Galach, I. Braun, P.G. Layer
- P6-14. HIGH-LEVEL EXPRESSION OF RECOMBINANT ACETYLCHOLINESTERASES IN SILKWORM LARVAE  
L. Li, Y. Wang, D. Ip, **D.C. Wan**
- P6-15. A TRANSCRIPTIONAL REGULATION OF NEURONAL ACHE BY DIOXIN  
**H.Q. Xie**, B. Zhao

**Session 7: Diseases related to cholinesterases, and cholinesterase inhibitors therapy.**

- P7-1. GESTATIONAL DIABETES MELLITUS DECREASES BUTYRYLCHOLINESTERASE ACTIVITY AND CHANGES ITS RELATIONSHIP WITH LIPIDS.  
L.O. Guimarães, T.E. Setoguchi, G.F. Bono, M.B. Brandão, E.A.C.F. Maia, I.C.R. dos Santos, G. Picheth, R.R. Réa, A.C.R. de A. Faria, **R.L.R. Souza**, L.F. Alle
- P7-2. BIS(12)-HUPYRIDONE PROTECTS GLUTAMATE-INDUCED NEURONAL LOSS VIA INHIBITING GSK3 $\beta$   
**W. Cui**, H.H.N. Chan, J. Luo, S. Hu, W. Li, Y. Zhao, S. Mak, J. Rong, P.R. Carlier, Y. Han
- P7-3. NEW POTENTIAL ANTICHOLINESTERASIC BARBITURATE DERIVATIVES SYNTHETIZED  
S.P. de Souza, A.P. Guimarães, S.S. Valverde, A.B. Lima, K.C.S. Lima, J.D.F. Villar, **T.C.C. França**, A.L.S. Lima

- P7-4. PROTEIN-ANCHORING THERAPY FOR DELIVERING ACETYLCHOLINESTERASE TO THE NEUROMUSCULAR JUNCTION  
**M. Ito**, Y. Suzuki, T. Okada, T. Fukudome, T. Yoshimura, A. Masuda, S. Takeda, E. Krejci, K. Ohno
- P7-5. HUPRINE-BASED HETERODIMERS ASSEMBLED BY CLICK AND IN SITU CLICK CHEMISTRY AS MULTI-TARGET DIRECTED LIGAND FOR A POTENTIAL TREATMENT OF ALZHEIMER DISEASE  
**L. Jean**, C. Ronco, E. Oueis, C. Sabot, F. Nachon, E. Carletti, J.-P. Colletier, M. Weik, P.-Y. Renard
- P7-6. K298 AND K524: SMALL QUATERNARY AChE INHIBITORS, THEIR PHARMACOKINETICS AND PHARMACODYNAMICS EFFECT AFTER APPLICATION OF THERAPEUTIC DOSES  
**J. Zdarova Karasova**, M. Hroch, K. Musilek, F. Zemek, V. Sepsova, Z. Krenkova, L. Drtinova, K. Kuca
- P7-7. THE INTERACTION OF TACRINE AND 7-MEOTA WITH NEURONAL NICOTINIC RECEPTOR  
**J. Krusek**, V. Sepsova, O. Soukup, J. Zdarova Karasova, F. Vyskocil
- P7-8. ROLE OF DIFFERENT CHOLINESTERASE MOLECULAR FORMS IN HEART PHYSIOLOGY  
**M. Kucera**, V. Farar, M. Matus, E. Kralova, T. Stankovicova, J. Myslivecek, A. Hrabovska
- P7-9. COMPARATIVE STUDY OF INHIBITION POTENCY OF ALZHEIMER'S DISEASE DRUGS ON DIFFERENT NON-SYNONYMOUS SNPS OF ACETYLCHOLINESTERASE - AN *IN SILICO* APPROACH  
**P. Saravanaraman**, R. Boopathy
- P7-10. THE INTERACTION OF REVERSIBLE ACETYLCHOLINESTERASE INHIBITORS WITH THE NICOTINIC RECEPTORS - *IN VITRO* TESTING  
**V. Sepsova**, J. Krusek, O. Soukup, F. Zemek, L. Drtinova, J. Korabecny, Z. Krenkova, J. Zdarova Karasova
- P7-11. miRNA-132 AS A KEY FUNCTIONAL REGULATOR OF CHOLINERGIC REACTIONS TO ACUTE ISCHEMIC STROKE  
**S. Shenhar-Tsarfaty**, O. Engel, E. Ben Assayag, S. Berliner, A. Meisel, H. Soreq

### 3D Session.

- P3D-1. TEMPLATE DESIGNING FOR ALZHEIMER'S DISEASE DRUG: TOWARDS PREDICTION OF BEST KNOWN INHIBITORS FOR CHOLINESTERASES  
**L. Venkatachalam**, R. Boopathy

# SPONSORS



Government of the Republic of Tatarstan



*Liberté • Égalité • Fraternité*

**RÉPUBLIQUE FRANÇAISE**

Ambassade de France à Moscou



Defense Threat Reduction Agency  
Chemical & Biological Technologies  
Directorate



Russian Foundation for Basic Research



RussEndo



**ПИК-ФАРМА**

PIK-Pharma



Bruker Ltd. Moscow



European Molecular Biology Organization



Acta Naturae journal

